News for Healthier Living

Modified Personalized Cancer Vaccine Generates Powerful Immune Response

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVaxMI is safe, feasible, and improves the vaccine-specific immune response compared to previous trials of the platform. The findings are published in Cell.

July 10, 2025


July 13 2025

July 12 2025

July 11 2025

July 10 2025

July 9 2025

July 8 2025

July 7 2025

July 6 2025

July 5 2025

July 4 2025

July 3 2025

July 2 2025

July 1 2025

June 30 2025

June 29 2025